Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTianjin Medical University Second Hospital
About this trial
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma
Eligibility criteria
Qualifiers
Suspected or histologically confirmed urothelial carcinoma
Disqualifiers
History of or concurrent active malignancy other than urothelial carcinoma
Trial design
Treatments tested in this trial
- Multi-Component Liquid Biopsy for Urothelial Carcinoma
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
1The second hospital of Tianjin Medical University300000, Tianjin China
Sponsors and collaborators
Tianjin Medical University Second Hospital
Lead sponsor
Source ClinicalTrials.gov